Comparison of integrated Chinese and Western medicine with and without somatostatin supplement in the treatment of severe acute pancreatitis.
OBJECTIVE
To evaluate the therapeutic effect of the combined use of early short-term somatostatin and conventional integrated Chinese and Western medicine in treating severe acute pancreatitis.


METHODS
Sixty patients with severe acute pancreatitis were divided at random into a somatostatin group and a basic treatment group. Both groups received integrated traditional Chinese and Western medicine without surgery. For patients in the somatostatin group, somatostatin was infused intravenously 250 microg/h for 72 h; other medications were the same as in the basic treatment group. In both groups, comparisons of therapeutic effectiveness were made in terms of morbidity of organic dysfunction and mortality rate, and severity of the disease according to serum levels of C-reaction protein, scores of acute physiology and chronic health evaluation (APACHE II), and scores of Balthazar-CT.


RESULTS
The indexes for C-reaction protein levels on the fourth and seventh days, and APACHE II scores on the seventh day after treatment, were significantly improved in the somatostatin group than in the basic treatment group. The morbidity of organic dysfunction was lower in the somatostatin group than in the basic treatment group, although the difference was not statistically significant. There was no significant difference in mortality between the two groups.


CONCLUSIONS
We conclude that combined traditional Chinese and Western medicines with an early short-term use of somatostatin can improve the condition of patients with severe acute pancreatitis.
Xia
Qing
Q
Department of Integrated Traditional Chinese and Western Midicine, West China Hospital, Sichuan University, 37 Guoxuexiang, Chengdu 610041, Sichuan Province, China. xiaqing@medmail.com.cn
Yuan
Lin
L
Yang
Xiao-Nan
XN
Tang
Wen-Fu
WF
Jiang
Jun-Ming
JM
D018806:APACHE; D000208:Acute Disease; D000328:Adult; D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D009017:Morbidity; D010195:Pancreatitis / Q000188:drug therapy* / Q000401:mortality*; D012720:Severity of Illness Index; D013004:Somatostatin / Q000008:administration & dosage*; D019366:Western World
D013004:Somatostatin; D002097:C-Reactive Protein
Crit Care Med. 1981 Aug;9(8):591-7
7261642
Br J Surg. 2000 Mar;87(3):257-8
10718789
Aliment Pharmacol Ther. 1998 Mar;12(3):237-45
9570258
Radiology. 1985 Sep;156(3):767-72
4023241
Hua Xi Yi Ke Da Xue Xue Bao. 2001 Mar;32(1):92-5
12733366
Swiss Surg. 2000;6(5):235-40
11077488
Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Mar;35(2):204-8
15071917
Dig Dis Sci. 2000 Nov;45(11):2247-51
11215748
World J Gastroenterol. 2000 Feb;6(1):115-118
11819536
Intensive Care Med. 1998 Jan;24(1):37-9
9503220